Adocia Adocia
  • Adocia
    • About
    • History
    • Management
    • Board of directors
    • Advisory board
  • Products and platforms
    • Pipeline
    • Technology Platforms
  • Careers
    • The « Adocians »
    • HR policy
    • Work environment
    • Join us
  • Partnering
  • Investors
  • Media
  • Contact
    • Contact us
    • Map and accessibility
  • Investors
    • Regulated information
    • Stock information
    • Corporate governance
    • General meeting
  • Media
    • Press releases
    • Media
  • EN
    • FR

Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET)

Previous articleBioChaperone® Combo, a co-formulation of lispro and glargine, demonstrates both prandial and basal insulin time-action profiles in a single injection in type 2 diabetes, Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
Next articleAdocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes
Adocia
  • Adocia
  • Products and platforms
  • Careers
  • Partnering
  • Investors
  • Media
  • Contact
Contact us
+33(0)4 72 610 610 contact@adocia.com

Adocia
115 Avenue Lacassagne
69003 Lyon, France

2026 © Adocia

  • Site plan
  • Legal notice
  • Privacy policy and cookies policy
  • Managing cookies
Website by Un Brin de CampagneUn Brin de Campagne